



Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which 
progressive motor neuron degeneration causes paralysis and, ultimately, death. A subset of ALS 
cases are caused by mutations in superoxide dismutase (SOD1). These mutations compromise 
the structure of the protein, which cause it to misfold and aggregate. Protein aggregates including 
SOD1 are found in inclusion bodies in spinal cord sections of both familial and sporadic ALS 
patients. The role of these aggregates in disease pathogenesis is not well known, and the 
mechanism of motor neuron death in ALS remains a mystery. However, glutamate-induced 
excitotoxicity, which occurs when cells lose the ability to buffer intracellular calcium 
concentrations and die from over-excitation, has been shown to have a significant role in ALS 
motor neuron death. Healthy cells have efficient safety mechanisms to protect against 
excitotoxicity. For example, vitamin D3 upregulates the expression of calcium-binding proteins, 
which buffer rising intracellular calcium levels. Based on this, we hypothesize that vitamin D3 
supplementation can protect from glutamate-induced excitotoxicity in an ALS cell culture model. 
We treated motor neuron-like cells expressing an aggressive disease mutant, A4V SOD1, with 
vitamin D3 and measured its effect on cell viability. We show that vitamin D3 restores viability in 
cells expressing A4V SOD1 to that of cells expressing wild-type SOD1, suggesting that vitamin 
D3 can protect from SOD1-mediated motor neuron cell death. This finding may lead to 
implementation of vitamin D3 supplements as a complementary treatment method for ALS 
patients and encourage further research to improve intracellular calcium-buffering in ALS. 
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease 
characterized by motor neuron death and paralysis. No cure or significant treatment currently 
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exists for ALS, and the average life expectancy of patients ranges from 2-5 years. ALS cases are 
classified as either sporadic, having no known cause, or familial, being linked to genetic 
mutations that are causative of the disease. In a subset of familial ALS cases, mutations in the 
gene encoding Cu, Zn superoxide dismutase (SOD1) cause ALS.1 SOD1 is an enzyme that 
converts toxic free superoxide radicals into less harmful species. ALS-causing mutations in 
SOD1 are toxic gain-of-function mutations that destabilize SOD1’s native dimer structure, 
causing it to misfold and aggregate. Large, insoluble aggregates are found in inclusion bodies in 
spinal cord sections of both sporadic and familial ALS patients. However, the species thought to 
be responsible for cell toxicity are actually small, non-native oligomers that form in the early 
stages of protein aggregation.2 Specifically, the Dokholyan lab has previously shown that non-
native SOD1 trimers are highly toxic to motor neuron-like cells in culture.3  
The mechanism by which SOD1 induces toxicity is still unclear. However, glutamate-
induced excitotoxicity is known to act in conjunction with SOD1 aggregation to promote death 
in motor neurons in familial ALS.1 Glutamate-induced excitotoxicity results from dysregulation 
of gated calcium channels, leading to an overload of intracellular calcium. Dysregulation of 
calcium channels can arise from a variety of factors and plays an important role in motor neuron 
death in ALS.1 Two calcium channels found in motor neurons are α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors. In 
healthy neuronal cells, these receptors are activated by glutamate and allow calcium ions to enter 
the cell. Increasing the intracellular calcium concentration is necessary for many cellular 
functions such as the propagation of action potentials. However in ALS, glutamate is 
dysregulated and causes abnormally high levels of calcium to build up inside of the cell. Cell 
death resulting from increased calcium influx by glutamate receptors is called glutamate-induced 
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excitotoxicity. The only available treatment for ALS, riluzole, is thought to target AMPA or 
NMDA receptors and function by restricting calcium entry into the cell.4  
Vitamin D3, a steroid hormone, functions by binding to a transcription factor for 
intracellular calcium binding proteins like parvalbumin, calbindin, and calretinin.5 Increasing 
expression of these calcium-binding proteins could potentially improve calcium buffering 
capacity and confer protection to motor neuron cells experiencing calcium overload. It has been 
shown in a small study with ALS patients that supplementation with vitamin D3 for at least 9 
months slowed disease progression.6 Several other studies have also shown that vitamin D3 
supplementation has beneficial effects in SOD1 mouse and cell models of  ALS.5,7,8  
Therefore, we hypothesize that additional vitamin D3  supplementation may protect ALS-
affected motor neurons from glutamate-induced excitotoxicity. A4V is the most common SOD1 
mutation in the Americas, and is one of the most aggressive disease mutants of SOD1. Therefore, 
we used mouse NSC-34 cells expressing A4V SOD1 as a model for ALS in cell culture. Because 
the presence of trimers has been has been linked to disease toxicity, we aimed to show their 
formation in this particularly aggressive known disease mutant. First, we looked at whether A4V 
SOD1 forms toxic trimers in vitro.3 We confirmed the spontaneous formation of toxic trimer 
species from purified apo-A4V SOD1 protein after a one-week incubation at physiological pH 
and temperature (Figure 1 and 2). After verifying A4V trimer formation, we tested whether 
vitamin D3 supplementation could protect motor neuron-like cells expressing A4V SOD1. We 
found that vitamin D3 treatment protected motor neuron cells expressing A4V SOD1 from cell 






Aggregation assay of purified apo-SOD1 
Wild-type SOD1 and mutant A4V SOD1 purified from yeast, as previously published,2 were 
demetallated by dialysis in a 1L solution of 50mM NaCH3COO, 10mM EDTA, pH 3.8 for 1.5 
hours at 4°C. The samples were returned to physiological pH by dialysis in a 1L solution of 
20mM Tris, 150mM NaCl, pH 7.4 overnight at 4°C. The apo-SOD1 samples were incubated at 
100µM in 20mM Tris, 150mM NaCl, pH 7.4 at 37°C for 1 week. The samples were filtered 
through 0.22µm centrifuge filters and each run by FPLC through a ----Superdex 200 10/300GL 
size exclusion column, using 20mM Tris, 150mM NaCl, pH 7.4 as the running buffer. 
  
Dot blot of wild-type and A4V SOD1 with C4F6 antibody 
Immediately following separation on a Superdex 75 10/300GL size exclusion column, the 
separated oligomeric populations were spotted in duplicate onto PVDF membranes equilibrated 
in 20mM Tris, 150mM NaCl, pH 7.4 using a chilled Minifold I dot-blot system (S&S). One blot 
was stained with Ponceau S in 5% acetic acid. The other blot was immediately incubated with 
1:250 dilution of monoclonal mouse antibody C4F6 (Medimabs) in blocking buffer (TBS-T with 
5% nonfat dry milk) and left overnight at 4°C. Goat anti-mouse secondary antibody (Molecular 
Devices) diluted 1:1000 was used to visualize C4F6 binding. The blot was incubated with 
secondary antibody at room temperature protected from light for 1 hour before visualization on a 
SpectraMax i3 Multi-Mode Detection Platform. 
  
Transfection of pImCherry plasmids into NSC-34 cells 
In two wells of a 6-well plate, NSC-34 cells at approximately 80% confluency were transfected 
with either pImCherry_SOD1 or pImCherry_SOD1A4V plasmids. The pImCherry_SOD1 and 
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pImCherry_SOD1A4V plasmids were engineered such that the SOD1 or SOD1_A4V gene was 
inserted directly after an mCherry gene. Transfection was carried out by preparation of a master 
mix of 25:1 Opti-MEM:Lipofectamine 3000 and a DNA mix of 25:1 Opti-MEM:P3000 with 4µg 
plasmid DNA. For each well, 250µL of 1:1 master mix:DNA mix was incubated at room 
temperature for 10 minutes and then added to the wells. Cells were incubated in transfection 
media for 6 hours, then split into 50 wells (25 for pImCherry_SOD1 and 25 for 
pImCherry_SOD1A4V) of each 96-well plate and grown in differentiation media with 100mM 
retinoic acid at 37°C and 5% CO2. 
  
Vitamin D3 cell viability assay 
Five wells of each set of transfected cells were treated with either 0, 100, 250, 500, or 750nM 
calcitriol (the active metabolic form of vitamin D3) at 72 hours post-transfection. At this time, 
the cells were also given fresh differentiation media with 100mM retinoic acid. At 8 and 48 
hours post-treatment with calcitriol, cells were put under oxidative stress by incubation in 
500µM hydrogen peroxide for 30 minutes, mimicking the oxidative stress typical of ALS disease 
pathology. They were then stained with SYTOX Green Dead Cell Stain (Fisher Scientific). 
Using a SpectraMax i3 Multi-Mode Detection Platform and cell analysis software, the total 
number of cells and dead cells in each condition were measured. The total cell count was 
obtained by analysis of light transmission microscopy images of the wells, and the dead cell 
count was obtained by analysis of fluorescent imaging of the wells measured at λex = 456 nm / 
λem= 541 nm. Transfection efficiency was measured by analysis of fluorescent imaging of the 
wells measured at λex = 625 nm / λem= 713 nm, which indicated expression of mCherry (and 
therefore SOD1) in the cells. Statistical significance of results was determined using an 
uncorrected Fisher’s LSD test. 
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RESULTS 
A4V SOD1 generates toxic trimer species in vitro. Size exclusion chromatography was used to 
separate distinct oligomeric populations of aggregated samples of wild-type SOD1 and A4V 
SOD1 (Figure 1). The A4V SOD1 sample had a larger trimer/tetramer oligomer population (O1) 
than wild-type SOD1 and had little to no monomer population (M). Wild-type SOD1 had a larger 
dimer population (D) than A4V SOD1, as well as a distinct population of monomers. 
  
Trimeric SOD1 display a toxicity-associated epitope recognized by the C4F6 antibody. Dot 
blots of the three oligomeric populations (O1-trimers/tetramers; D-dimers; M-monomers) of 
wild-type and A4V SOD1 separated by size exclusion chromatography showed a species-
dependent reactivity to the C4F6 antibody (Figure 2). C4F6 antibody was raised in G93A SOD1 
mutant mice and positively stains inclusion bodies in spinal cord sections of ALS patients. 
Trimer/tetramer species for both wild type and A4V SOD1 had the greatest binding to C4F6 , in 
comparison to the dimer or monomer species. The monomer species for wild type SOD1 had 
little to no binding to the C4F6 antibody.  
  
Vitamin D3 treatment protects A4V SOD1-expressing cells from oxidative stress. Cells were 
put under oxidative stress by treatment with hydrogen peroxide at 8hrs and 48hrs post-treatment 
with vitamin D3. At 8hrs post-vitamin D3 treatment, there is no significant difference in survival 
between the cells expressing wild-type SOD1 and those expressing A4V SOD1 at any 
concentration of vitamin D3 after hydrogen peroxide treatment (Figure 3). At 48hrs post-vitamin 
D3 treatment, untreated and 100nM vitamin D3-treated populations of A4V SOD1-expressing 
cells have significantly increased cell death over the untreated wild-type SOD1 control 
(p=0.0001, p=0.04). At this time point, cells treated with at least 250nM of vitamin D3 had 
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viability restored to that of untreated wild-type SOD1-expressing cells (Figure 4). Vitamin D3 
treatment did not affect wild-type SOD1-expressing cells at either time point. 
 
DISCUSSION 
A4V SOD1 forms toxic trimers at physiological conditions. Based on previous research, we 
conclude that the first eluted peak on the size exclusion chromatography spectrum corresponds to 
trimer and tetramer oligomers of SOD1, the second eluted peak corresponds to dimers of SOD1, 
and the third eluted peak corresponds to monomeric SOD1 (Figure 1).2 Wild-type SOD1 formed 
very few trimer/tetramer oligomers (O1), whereas A4V SOD1 generated  a large amount of these 
species (Figure 1). The tendency of A4V SOD1 to form the trimer/tetramer species may result 
from the mutation’s destabilization of the native dimer structure of SOD1, which results in 
dissociation of the dimer structure followed by formation of a non-native trimer or tetramer 
species. As a result, the trimer/tetramer species formed more readily by A4V SOD1 are 
potentially the toxic agents that result from SOD1 mutations. Previous studies have shown that 
SOD1 toxicity is indeed linked to the presence of the trimer species of SOD1.3   
  
Trimer and tetramer oligomers react strongly with toxicity-associated C4F6 antibody. Dot 
blots of both wild-type SOD1 and A4V SOD1 show that the larger oligomeric species 
(trimers/tetramers) of SOD1 have strong reactivity to the monoclonal antibody, C4F6 (Figure 2). 
These results suggest that the epitope recognized by the antibody may be more exposed or 
present in the structure of the trimer/tetramer oligomers than in either the dimer or monomer 
structures. The C4F6 antibody marks toxic SOD1 species, as it was raised against mouse G93A 
SOD1 and specifically recognizes SOD1  in ALS disease-affected tissue.2  Therefore, these 
results support the identification of trimer species of SOD1 as toxic agents in ALS. 
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NSC-34 cell death is enhanced by A4V SOD1 expression. The cell viability assay of NSC-34 
motor neuron-like cells showed a significant difference between cell death in cells expressing 
wild-type SOD1 and those expressing A4V SOD1 (Figure 3). Transfection efficiency measured 
by mCherry expression was approximately 85%, indicating successful expression of both 
mCherry and the inserted SOD1 genes. We have therefore confirmed previously published 
results that the presence of A4V SOD1 enhances cell death. To further support these results, we 
will follow up these experiments with confirmation of A4V SOD1 presence in the cells by 
western blot.  
 
Vitamin D3 rescues motor neurons from A4V SOD1-induced cell death. We showed a rescue 
effect of vitamin D3 treatment on motor neuron viability in culture (Figures 3 & 4). The viability 
of cells expressing A4V SOD1 was restored to that of those expressing wild-type SOD1 by 
treatment with at least 250nM vitmain D3. This supports the hypothesis that vitamin D3 has a 
protective effect on motor neuron cells that experience A4V SOD1-induced toxicity. These 
protective effects were only visible at 48hrs post-vitamin D3 treatment. Because vitamin D3 acts 
by binding to and regulating a transcription factor for intracellular calcium-binding proteins, we 
expect the effects of vitamin D3 to take more than 8hrs to influence cell viability. In the future, 
we plan to use a fluorescent calcium dye to monitor calcium concentrations in the cell with and 
without vitamin D3 treatment. This will allow us to determine the intracellular calcium 
concentrations at time points leading up cell death following vitamin D3 treatment and better 
predict the mechanism by which vitamin D3 treatment is conferring a protective effect on the 
cells transfected with A4V SOD1.  
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Our preliminary data suggest that vitamin D3 has a significant effect on motor neuron 
death and justifies further exploration of the effects of vitamin D3 on motor neuron cells in ALS. 
Based on these results, glutamate-induced excitotoxicity remains an important component of 
motor neuron death in SOD1-linked ALS patients. Future studies should investigate the 
mechanism by which excitotoxicity occurs in SOD1-induced cases of ALS, and explore possible 
routes to stop or slow its progression in the development of novel therapeutics. 
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Figure 1: Size exclusion chromatography spectra. The overlaid size exclusion 
chromatography spectra from the separation of wild-type SOD1 (SOD1WT) and A4V SOD1 
(SOD1A4V). The brackets indicate the volumes from which oligomeric populations were drawn 







Figure 2: Dot blots of wild-type SOD1 and A4V SOD1 with C4F6. Blots of wild-type SOD1 
(WT) and A4V SOD1 (A4V) with C4F6 antibody (IB: C4F6) and their respective duplicate blots 







Figure 3: Cell viability assays at 8hrs post-vitamin D3 treatment. The percentage of dead 
cells in each cell population at the three time points. The error bars represent the standard error 
of the percentage of dead cells. The grey bars indicate the cell populations that were transfected 
with SOD1 WT. The red bars indicate the cell populations were transfected with SOD1 A4V. 
The concentrations given on the x-axis are the concentrations of vitamin D3 given to the cells. 
Statistical significance was determined with respect to the SOD1 WT 0 nM vitamin D3 condition 






Figure 4: Cell viability assays at 48hrs post-vitamin D3 treatment. The percentage of dead 
cells in each cell population at the three time points. The error bars represent the standard error 
of the percentage of dead cells. The grey bars indicate the cell populations that were transfected 
with SOD1 WT. The red bars indicate the cell populations were transfected with SOD1 A4V. 
The concentrations given on the x-axis are the concentrations of vitamin D3 given to the cells. 
Statistical significance was determined with respect to the SOD1 WT 0 nM vitamin D3 condition 
using an uncorrected Fisher’s LSD test (***p=0.0001; *p=0.04). 
